enGene Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today...
EnCapsid Therapeutics Inc., the pioneer in synthetic virology, has obtained results to show that its modular and versatile capsid modification technology can be used...
Hemab Therapeutics, a biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombosis disorders, unveiled its lead candidate, HMB-001, a novel bispecific antibody...
Global biotherapeutics leader CSL Behring announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational adeno-associated virus...
